Pharmafile Logo

News and Press Releases

Medable Releases New Digital Oncology Trial Offering to Reduce Complexity for Sites, Sponsors, Patients, and Caregivers

Integrated solution with self-service capabilities simplifies trial experience for all 13 May 2025 -- California, US -- Medable Inc., a leading provider of clinical development and eCOA technology, today announced...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 13, 2025

Medable
media@medable.com
525 University Ave Suite A70 Palo Alto, CA 94301

Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025

Analysis of EFX results with AI-based digital pathology underscores the potential value in evaluating histopathology response Data contribute to growing body of support around the anti-fibrotic activity of EFX in...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 10, 2025

Akero Therapeutics
601 Gateway Boulevard, Suite 350 South San Francisco, CA 94080 (650) 487-6488

Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Trial in the New England Journal of Medicine

Results support potential benefit of efruxifermin (EFX) to elicit fibrosis improvement in patients with compensated cirrhosis (F4 fibrosis) due to MASH 96-week data from SYMMETRY trial presented at EASL Congress 2025...

Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: May 9, 2025

Akero Therapeutics
601 Gateway Boulevard, Suite 350 South San Francisco, CA 94080 (650) 487-6488

iOnctura commences randomized Phase I/II study in non-small cell lung cancer

First patient dosed in study investigating roginolisib + dostarlimab +/- docetaxel in patients with NSCLC who have progressed on prior immunotherapy/chemo Study will evaluate safety of the combination and explore...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 8, 2025

iOnctura
enquiries@ionctura.com
Campus Biotech Innovation Park Avenue Sécheron 15
 1202 Genève
 Switzerland

European Commission approves TREMFYA (guselkumab), the first dual-acting IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Crohn’s disease

TREMFYA (guselkumab) induction therapy administered either intravenously (GALAXI 2 and 3) or subcutaneously (GRAVITI) achieved the co-primary endpoints of clinical remissiona and endoscopic responseb at Week 12 compared to placebo...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 7, 2025

Johnson & Johnson Innovative Medicine
mediaenquiries@its.jnj.com
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG

PlaqueTec announces positive early research findings from interim analysis in BIOPATTERN trial

Pre-specified interim analysis reveals differences in protein concentration between systemic blood and blood from diseased coronary arteries Safety and functionality data for the updated Liquid Biopsy System supports continuation of...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 6, 2025

PlaqueTec
info@plaquetec.com
Maia Building (B270) Babraham Research Campus Cambridge CB22 3AT

Redx presents Phase 1 data supporting RXC008 as a novel and well tolerated drug candidate in development for the potential treatment of fibrostenotic Crohn’s disease

Orally administered pan-ROCK inhibitor demonstrated intestinal tissue exposure and target engagement with minimal plasma concentrations A Phase 2 study is being planned. 6 May 2025 -- Alderley Park, UK --...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 6, 2025

Redx Pharma
info@redxpharma.com
Block 33 Mereside, Alderley Park Alderley Edge Macclesfield SK10 4TG UK

Domain Therapeutics Presents Novel Data Addressing Key Challenges in Oncology at AACR 2025

Phase I clinical results of DT-9081, an EP4 receptor antagonist, allowed selection of recommended Phase II dose (RP2D) for further development in solid tumors Preclinical data of DT-7012 position this...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 30, 2025

Domain Therapeutics
contact@domaintherapeutics.com
PARC D'INNOVATION 220 Boulevard Gonthier D'Andernach 67400 Strasbourg - Illkirch - France

Iksuda to present growing ADC pipeline at AACR

Introduces the ProAlk payload series to address the growing challenge of ADC sequencing IKS04 to enter clinical development for gastrointestinal cancers by end of 2025 PermaLink offers stable and scalable...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 25, 2025

Iksuda
The Biosphere, Draymans Way, Newcastle Helix Newcastle upon Tyne NE4 5BX

Bioxodes announces positive Phase 2a interim data for BIOX-101 in intracerebral hemorrhagic stroke patients

Primary endpoint met, no drug-related serious adverse events Positive hematoma and edema volume evolution Recruitment stopped early due to positive exploratory and efficacy outcomes Preparations underway to initiate Phase 2b...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 24, 2025

Bioxodes
info@bioxodes.com
Parc d'activités Aéropole Rue Santos-Dumont, 1 6041 Gosselies, Belgique

Liverpool City Region set to become global powerhouse in new front for fighting disease and driving wellbeing

23 April 2025 -- Liverpool, UK -- Liverpool City Region is set to become a global powerhouse in a new front to tackle deadly diseases and improve wellbeing. More than...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 23, 2025

The University of Liverpool
Foundation Building Brownlow Hill Liverpool L69 7ZX

Pharming receives positive recommendation from NICE for Joenja▼(leniolisib) as a treatment for APDS

Joenja® is the first and only medicine specifically for APDS to be reimbursed within the NHS Recommended for adult and pediatric patients 12 years of age and older with activated...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 23, 2025

Pharming Group NV
info@pharming.com
Pharming Group N.V. Vondellaan 47 2332 AA Leiden The Netherlands

EsoCap to Present Key Phase II Results on Novel Drug Delivery System in Eosinophilic Esophagitis at DDW 2025

New insights on safety, adherence, and patient satisfaction with ESO-101 to be presented on May 3, 2025, at DDW 2025 ESO-101 features EsoCap’s proprietary drug delivery technology to enable localized...

Category: Biotechnology, Clinical Trials, Drug Delivery, Drug Discovery, Pharmaceutical
Posted: April 22, 2025

EsoCap Biotech
Malzgasse 9, CH-4052 Basel

Novadip reports key nonclinical and interim clinical data for NVDX3, its off-the-shelf allogenic product,in spine fusion

NVDX3 elicited bone formation as early as 12 weeks and functional fusion by 26 weeks in ovine posterolateral fusion (PLF) model In phase 1b/2a clinical trial, early bone fusion was...

Category: Biotechnology, Clinical Trials, Other
Posted: April 22, 2025

Novadip
info@novadip.com
Watson & Crick Hill, Rue Granbonpré 11, 1435 Mont-Saint-Guibert, Belgium

HUTCHMED Completes Patient Enrollment of a Phase II Registration Study of Savolitinib in Gastric Cancer in China

22 April 2025 -- Hong Kong, Shanghai and New Jersey, US -- HUTCHMED today announces that it has completed enrollment of the registration phase of its Phase II trial of...

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 22, 2025

HUTCHMED
48th Floor, Cheung Kong Center 2 Queen's Road Central, Hong Kong